Medical firm Getinge jumps as rising orders fuel profit beat
Adds share move in paragraph 2, analyst comment in -7
By Greta Rosen Fondahn
July 18 (Reuters) -Swedish medical equipment maker Getinge GETIb.ST beat second-quarter earnings forecasts on Thursday as its order intake rose despite some problems with its packaging and heart products.
The company's shares were up 7% in early Stockholm trading.
Getinge's earnings before interest, tax and amortisation (EBITA), adjusted for items affecting comparability, were 981 million Swedish crowns ($93 million) in the quarter, almost double the 495 million crowns reported a year earlier.
That beat analysts' consensus forecast of 829 million crowns, according to company-provided data.
Getinge has struggled to resolve quality problems with its heart pumps and with sterile packaging of products for heart-lung support systems, which has squeezed its margins and weighed on its shares since the second quarter of last year.
JPMorgan said Getinge's Acute Care Therapies (ACT) segment - its biggest business area that makes heart and intensive care products - drove the earnings beat, despite the quality issues.
"ACT performance is blow-out vs earlier commentary from the company," the brokerage said in a note to clients.
In May, Getinge said it would pause promotional activities and limit sales for some of its heart products in the United States, after the U.S. Food and Drug Administration (FDA) advised healthcare facilities to move away from the devices.
"We have accelerated improvement measures and the schedule for the next generation of these products," CEO Mattias Perjos said in a statement, adding it was too early to note any sales trend in the short term.
The maker of products for surgery, intensive care and sterilisation said its orders rose 7.8% organically in April-June to 8.41 billion crowns.
($1 = 10.5502 Swedish crowns)
Reporting by Greta Rosen Fondahn in Gdansk; Editing by Milla Nissi and Mark Potter
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
